Solos Endoscopy Inc. (OTC:SNDY) reported $125,791 in fourth-quarter sales, a 9.2 percent uptick compared with its third-quarter sales.
The Boston-based company, which makes endoscopic instruments and imaging equipment, said the increase over the $115,159 worth of sales transactions it posted during Q3 2009 was consistent with its full-year results.
Solos said it plans to release its Q4 and full-year financial results "soon." According to regulatory filings, however, its full-year 2009 sales should amount to $436,880, up 1.3 percent compared with $431,214 during 2008.
Solos didn’t escape last year unscathed, however. The economic climate forced it to sell a pair of product lines back to their original owner. The company sold the OvaScope and MastaScope product lines, which are used to detect different types of cancer in the breast and ovaries, back to Lifeline Biotechnologies Inc. of Reno, Nev.
Solos purchased the technologies from Lifeline in February 2007, intending to develop a market for the products. But company officials said economic constraints forced them to change tactics and focus on their core suite of endoscopy products instead.